MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
Pluristem Therapeutics Total Assets 2011-2026 | PSTI
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Pluristem Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.7 M | 39.5 M | 50.8 M | 68.1 M | 93.5 M | 65.5 M | 31.3 M | 39 M | 37.5 M | 45.9 M | 68.2 M | 74 M | 68.3 M | 47.4 M | 46 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 93.5 M | 31.3 M | 54.3 M |
Quarterly Total Assets Pluristem Therapeutics
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.6 M | 33.7 M | 38.7 M | 37.4 M | 30.9 M | 35.4 M | 39.5 M | - | 41.6 M | 44.5 M | 50.8 M | 56.2 M | 59.9 M | 59.8 M | 68.1 M | 79.1 M | 81.2 M | 83.7 M | 93.5 M | 93.5 M | 52.3 M | 59 M | 65.5 M | 65.5 M | 24.9 M | 27.6 M | 31.3 M | 31.3 M | 24.3 M | 30.9 M | 39 M | 43 M | 44.7 M | 31 M | 37.5 M | 37.5 M | 32.3 M | 40.2 M | 45.9 M | 45.9 M | 56 M | 60.3 M | 68.2 M | 68.2 M | 58.3 M | 63.8 M | 74 M | 74 M | 71.3 M | 65.5 M | 68.3 M | 68.3 M | 79.1 K | 81.4 M | 47.4 M | 47.4 M | 49.6 M | 49.8 M | 46 M | 46 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 93.5 M | 79.1 K | 51.4 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | France |
 |
Esperion Therapeutics
ESPR
|
466 M | $ 3.13 | 0.39 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
2.84 B | $ 45.86 | 3.23 % | $ 12.5 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Fortress Biotech
FBIO
|
186 M | $ 2.51 | 2.03 % | $ 70 M | USA |
 |
Athira Pharma
ATHA
|
92.2 M | - | - | $ 269 M | USA |
 |
Galapagos NV
GLPG
|
3.41 B | $ 28.95 | 1.97 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
21.1 B | $ 27.7 | 0.59 % | $ 17.1 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
21.4 B | $ 8.37 | 1.2 % | $ 6.83 B |  Spain |
 |
Genprex
GNPX
|
10.2 M | $ 0.9 | 1.28 % | $ 839 K | USA |
 |
BioNTech SE
BNTX
|
22 B | $ 94.84 | -0.69 % | $ 27.2 B | Germany |
 |
InflaRx N.V.
IFRX
|
55.2 M | $ 2.44 | 24.11 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
24.9 M | $ 0.81 | 2.15 % | $ 6.7 M |  Australia |
 |
Ionis Pharmaceuticals
IONS
|
3.52 B | $ 76.26 | 1.34 % | $ 12.2 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
78.8 M | - | - | $ 231 M | USA |
 |
Kamada Ltd.
KMDA
|
379 M | $ 8.25 | 0.49 % | $ 260 M |  Israel |
 |
INmune Bio
INMB
|
32.4 M | $ 1.55 | 0.65 % | $ 38.4 M | USA |
 |
Kymera Therapeutics
KYMR
|
1.74 B | $ 85.73 | 3.65 % | $ 7.24 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
35 M | $ 12.98 | -3.49 % | $ 1.72 B | Australia |
 |
ACADIA Pharmaceuticals
ACAD
|
1.19 B | $ 22.93 | 2.6 % | $ 3.8 B | USA |
 |
Liquidia Corporation
LQDA
|
328 M | $ 42.33 | 5.48 % | $ 3.64 B | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.55 | 1.43 % | $ 5.84 M | Israel |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Mirum Pharmaceuticals
MIRM
|
843 M | $ 107.42 | 1.52 % | $ 5.39 B | USA |
 |
MannKind Corporation
MNKD
|
792 M | $ 4.01 | 40.03 % | $ 1.23 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
433 M | $ 23.48 | 0.26 % | $ 2.99 B | USA |
 |
Nanobiotix S.A.
NBTX
|
67.8 M | $ 41.5 | 19.36 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |